These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 2183607)

  • 1. Pathophysiologic basis for the use of third-generation cephalosporins.
    Neu HC
    Am J Med; 1990 Apr; 88(4A):3S-11S. PubMed ID: 2183607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftizoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Richards DM; Heel RC
    Drugs; 1985 Apr; 29(4):281-329. PubMed ID: 3888599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Third-generation cephalosporins: a critical evaluation.
    Barriere SL; Flaherty JF
    Clin Pharm; 1984; 3(4):351-73. PubMed ID: 6432420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New insights into the activity of third-generation cephalosporins against pneumonia-causing bacteria.
    Jones RN; Erwin ME; Bale M
    Diagn Microbiol Infect Dis; 1992 Jan; 15(1):73-80. PubMed ID: 1580897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The activity of BMY 28142 a new broad spectrum beta-lactamase stable cephalosporin.
    Neu HC; Chin NX; Jules K; Labthavikul P
    J Antimicrob Chemother; 1986 Apr; 17(4):441-52. PubMed ID: 3486862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serious pediatric infections.
    Kaplan SL
    Am J Med; 1990 Apr; 88(4A):18S-24S. PubMed ID: 2183605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.
    Nishino T; Otsuki M; Hatano K; Nishihara Y
    Chemotherapy; 1994; 40(3):167-82. PubMed ID: 8205935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftazidime: in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics.
    Phillips I; Warren C; Shannon K; King A; Hanslo D
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():23-31. PubMed ID: 19802967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the in vitro and in vivo antibacterial activities of cefepime (BMY-28142) with ceftazidime, cefuzonam, cefotaxime and cefmenoxime.
    Masuyoshi S; Hiraoka M; Inoue M; Tomatsu K; Hirano M; Mitsuhashi S
    Drugs Exp Clin Res; 1989; 15(1):1-10. PubMed ID: 2663406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antibacterial activity and beta-lactamase stability of eleven oral cephalosporins].
    Bauernfeind A; Jungwirth R; Schweighart S; Theopold M
    Infection; 1990; 18 Suppl 3():S155-67. PubMed ID: 2079378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Barradell LB; Bryson HM
    Drugs; 1994 Mar; 47(3):471-505. PubMed ID: 7514976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug utilisation review (DUR) of the third generation cephalosporins. Focus on ceftriaxone, ceftazidime and cefotaxime.
    Adu A; Armour CL
    Drugs; 1995 Sep; 50(3):423-39. PubMed ID: 8521766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Third generation cephalosporins.
    Donowitz GR
    Infect Dis Clin North Am; 1989 Sep; 3(3):595-612. PubMed ID: 2671141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Review of oral cephalosporins. Basis for a rational choice].
    Forti IN
    Medicina (B Aires); 1994; 54(5 Pt 1):439-58. PubMed ID: 7658980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mechanisms of resistance in Enterobacteriaceae towards beta-lactamase antibiotics].
    Susić E
    Acta Med Croatica; 2004; 58(4):307-12. PubMed ID: 15700687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in vitro activities of cefotaxime and ceftizoxime (FK749): new cephalosporins with exceptional potency.
    Greenwood D; Pearson N; Eley A; O'Grady F
    Antimicrob Agents Chemother; 1980 Mar; 17(3):397-401. PubMed ID: 6252829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro antimicrobial activity of Cefpirome: a new fourth-generation cephalosporin against clinically significant bacteria.
    Hafeez S; Izhar M; Ahmed A; Zafar A; Naeem M
    J Pak Med Assoc; 2000 Aug; 50(8):250-2. PubMed ID: 10992706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cephalosporins and related antibiotics: an overview.
    Turck M
    Rev Infect Dis; 1982; 4 Suppl():S281-7. PubMed ID: 7178754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gram-negative bacilli resistant to third-generation cephalosporins: beta-lactamase characterization and susceptibility to Sch 34343.
    Medeiros AA; Hare R; Papa E; Adam C; Miller GH
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():119-32. PubMed ID: 3875602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The in-vitro activity of cefodizime: a review.
    Soussy CJ; Chanal M; Kitzis MD
    J Antimicrob Chemother; 1990 Nov; 26 Suppl C():13-21. PubMed ID: 2074248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.